The Use of Circulating Tumor DNA in the Management of Cutaneous, Thoracic and Breast Malignancies

Moderator(s)

• 

  Genevieve Boland, MD, PhD (she/her/hers)

  Vice Chair of Research, Section Head Melanoma/Sarcoma Surgery
  Massachusetts General Hospital

  Disclosure(s): Ankyra Therapeutics: Advisor (Ongoing), Consultant (Ongoing), Stocks (Ongoing); InterVenn Bioscience: Advisor (Terminated, November 4, 2022), Consultant (Terminated, November 4, 2022), Research Grant (Terminated, November 4, 2022); Iovance Biotherapeutics: Advisor (Ongoing); Merck: Advisor (Ongoing), Consultant (Ongoing); Nektar Therapeutics: Advisor (Terminated, July 1, 2021); Novartis: Advisor (Terminated, November 4, 2022); Olink Proteomics: Research Grant (Ongoing); Palleon Pharmaceuticals: Research Grant (Terminated, November 4, 2022); Teiko Bio: Research Grant (Ongoing)

Presentations:

• 2:16 PM – 2:31 PM

  The Use of ctDNA in the Management of Cutaneous Malignancies: Current Use and Future Directions
  

  Presenter: Kelly Olino, MD (she/her/hers) – Yale School of Medicine
• 2:32 PM – 2:47 PM

  The Use of ctDNA in the management of thoracic malignancies: Current use and future directions
  

  Presenter: Maximilian Diehn, MD, PhD – Stanford University
• 2:48 PM – 3:04 PM

  The Use of ctDNA in the Management of Breast Malignancies: Current use and Future Directions
  

  Presenter: Mark Jesus M. Magbanua, PhD (he/him/his) – University of California San Francisco
• 3:05 PM – 3:15 PM

  Questions and Discussion
  

  Panelist: Kelly Olino, MD (she/her/hers) – Yale School of Medicine

  Panelist: Maximilian Diehn, MD, PhD – Stanford University